97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037220 | 2020-10-01 | 2020-08-27 | A randomized controlled clinical trial of Qingdai(indigo naturalis) in the treatment of mild to moderate active ulcerative colitis | A randomized controlled clinical trial of Qingdai(indigo naturalis) in the treatment of mild to moderate active ulcerative colitis | ulcerative colitis | Traditional Chinese medicine group:Qingdai (indigo naturalis);Western medicine group:Mesalazine granules; | Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine | NULL | Recruiting | Both | Traditional Chinese medicine group:40;Western medicine group:40; | China | |||
| 2 | ITMCTR2000003772 | 2020-10-01 | 2020-08-27 | A randomized controlled clinical trial of Qingdai(indigo naturalis) in the treatment of mild to moderate active ulcerative colitis | A randomized controlled clinical trial of Qingdai(indigo naturalis) in the treatment of mild to moderate active ulcerative colitis | ulcerative colitis | Traditional Chinese medicine group:Qingdai (indigo naturalis);Western medicine group:Mesalazine granules; | Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine | NULL | Recruiting | Both | Traditional Chinese medicine group:40;Western medicine group:40; | China | |||
| 3 | JPRN-jRCTs031190156 | 09/12/2019 | 09/12/2019 | IN for practical use | Study on efficacy and safety of indigo naturalis in patients with intractable ulcerative colitis. | ulcertive colitis | administration of one indigo naturalis FC enteric-coated tablet (including 0.5g indigo naturalis per tablet)twice a day for 4 weeks | Kanai Takanori | NULL | Recruiting | >= 16age old | Not applicable | Both | 100 | Phase 3 | Japan |
| 4 | JPRN-UMIN000029633 | 2017/12/27 | 20/10/2017 | The efficacy of indigo naturalis-containing suppository in patients with active ulcerative colitis. | The efficacy of indigo naturalis-containing suppository in patients with active ulcerative colitis. - The efficacy of indigo naturalis-containing suppository in patients with active ulcerative colitis. | ulcerative colitis | administration of the suppository ,which contains 0.05g indigo naturalis, for 4 weeks | Keio University School of Medicine | NULL | Complete: follow-up complete | 18years-old | Not applicable | Male and Female | 10 | Not selected | Japan |
| 5 | JPRN-jRCTs071180073 | 08/08/2017 | 22/03/2019 | Further maintenance of remission for a year after Qing-Dai withdrawal in ulcerative colitis treatment:randomized controlled trial | Further maintenance of remission for a year after Qing-Dai withdrawal in ulcerative colitis treatment:randomized controlled trial - None | Ulcerative colitis Ulcerative colitis | arm A :stop oral administration of indigo naturalis arm B :continue oral administration of indigo naturalis | Kitazono Takanari | NULL | Complete | >= 16age old | Not applicable | Both | 40 | Phase 2 | Japan |
| 6 | JPRN-UMIN000021460 | 2015/10/20 | 13/03/2016 | Chromoendoscopic method using an acetic acid indigocarmine mixture for diagnostic accuracy in delineating margin of colitic cancer. | Chromoendoscopic method using an acetic acid indigocarmine mixture for diagnostic accuracy in delineating margin of colitic cancer. - Chromoendoscopy of colitic cancer using an acetic acid indigocarmine mixture | patients with ulcerative colitis had high risk of colitic cancer.A:patients suspected dysplasia(low/high grade) or cancer.B:patients had plan of treatment of the dysplasia or cancer. | 40mL AIM solution (0.6% acetic acid with 0.4% IC) was sprinkled onto the lesions and images were recorded. | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 30 | Not selected | Japan |
| 7 | JPRN-UMIN000017359 | 2015/05/07 | 01/05/2015 | Investigation of the safety of Indigo naturalis for the patients with ulcerative colitis | Investigation of the safety of Indigo naturalis for the patients with ulcerative colitis - Investigation of the safety of Indigo naturalis for the patients with ulcerative colitis | ulcerative colitis | Oral administration of Indigo naturalis 2g/day, 4 weeks | Osaka University, Graduate School of Medicine, Department of Gastroenterology and Hepatology | NULL | Recruiting | 20years-old | 95years-old | Male and Female | 20 | Not selected | Japan |